Sloan-Kettering Institute for Cancer Research

Sloan-Kettering Institute

Other

Princeton University

Fundacao D. Anna Sommer Champalimaud E Dr. Carlos Montez Champalimaud

Fundação D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud

The Rogosin Institute

Carlos Cordon-Cardo

Barry Scott Smith

Lloyd J Old

Kenneth O Lloyd

Herbert F Oettgen

Myron R Melamed

Connie L Finstad

Wolfgang J Rettig

Gerardo Fernandez

Michael Donovan

Faisal Khan

Gloria C Li

John L Lewis, Jr

Jose Costa

Stephen Mastorides

Honghai Ouyang

Ricardo Mesa-Tejada

Andrew C Koff

Arnold J Levine

Howard Scher

M Jules Mattes

Junichi Sakamoto

Cathy A Finlay

Neil H Bander

Willet F Whitmore

Eileen A Friedman

Bernd R Anger

Stefan Hamann

Bernice Schiller

Warren E Enker

Willet F Whitemore, Jr

Stephen Fogarasi

Yves Fradet

Karen Chorney

Yevgen Vengrenyuk

John P Koulos

Jason Alter

Hans-Joachim Feickert

Douglas Powell

Ali Tabesh

Valentina Bayer Zubek

Mryon R Melamed

Joel Sheinfeld

Daniel Petrylak

Josep Domenech

Mireia Castilla Martin

Douglas A Powell

Clinical information, molecular information and/or computer-generated morphometric information is used in a predictive model for predicting the occurrence of a medical condition. In an embodiment, a model predicts risk of prostate cancer progression in a patient, where the model is based on features including one or more (e.g., all) of preoperative PSA, dominant Gleason Grade, Gleason Score, at least one of a measurement of expression of AR in epithelial and stromal nuclei and a measurement of expression of Ki67-positive epithelial nuclei, a morphometric measurement of average edge length in the minimum spanning tree (MST) of epithelial nuclei, and a morphometric measurement of area of non-lumen associated epithelial cells relative to total tumor area. In some embodiments, the morphometric information is based on image analysis of tissue subject to multiplex immunofluorescence and may include characteristic(s) of a minimum spanning tree (MST) and/or a fractal dimension observed in the images.

Method and system for determining the risk of occurrence of prostate cancer

Clinical information, molecular information and/or computer-generated morphometric information is used in a predictive model for predicting the occurrence of a medical condition. In an embodiment, a model predicts whether a patient is likely to have a favorable pathological stage of prostate cancer, where the model is based on features including one or more (e.g., all) of preoperative PSA, Gleason Score, a measurement of expression of androgen receptor (AR) in epithelial and stromal nuclei and/or a measurement of expression of Ki67-positive epithelial nuclei, a morphometric measurement of a ratio of area of epithelial nuclei outside gland units to area of epithelial nuclei within gland units, and a morphometric measurement of area of epithelial nuclei distributed away from gland units. In some embodiments, quantitative measurements of protein expression in cell lines are utilized to objectively assess assay (e.g., multiplex immunofluorescence (IF)) performance and/or to normalize features for use within a predictive model.

System for evaluating a pathological stage of prostate cancer

This invention provides a method for determining the aggressiveness of a prostate carcinoma comprising: (a) obtaining a sample of the prostate carcinoma; and (b) detecting the presence of p27 protein in the prostate carcinoma, the absence of p27 indicating that the prostate carcinoma is aggressive. This invention also provides a method for diagnosing a beign prostate hyperplasia comprising: (a) obtaining an appropriate sample of the hyperplasia; and (b) detecting the presence of the p27 RNA, a decrease of the p27 RNA indicating that the hyperplasia is beign. This invention provides various uses of p27 in prostate cancer. Finally, this invention also provides different marker for prostate cancer.

Markers for prostate cancer

The present invention provides a method for creating a frozen tissue array. An oil in a liquid form is added into a recipient block containing frozen tissue cores where the oil has a freezing point lower than the freezing point of the tissue cores; and the recipient block containing the oil is cooled to a temperature about equal to or below the freezing point of the oil; the subsequently frozen oil locks the frozen cores in the recipient block. The oil may also be added to the recipient block prior to inserting the frozen tissue cores. The recipient block may be formed using a cryoarray device comprising a mold plate, an ejector plate, mold alignment pins, ejector pins, and cryoarray pins. Such method may be used for preparing frozen sections with multiple tissue specimens for assays such as in-situ hybridization and immunohistochemistry.

Method for creating a frozen tissue array

This invention provides a method of diagnosing a predisposition to cancer in a subject comprising: (a) obtaining a nucleic acid sample from the subject; and; (b) determining whether one or more of the subject's Ku70 alleles or regulatory regions to those alleles are deleted or different from the wild type so as to reduce or eliminate the subject's expression of polypeptide having tumor suppressor activity. This invention also provides a method of assessing the severity of cancer in a subject comprising: (a) obtaining a nucleic acid sample from the subject; and (b) determining whether one or more of the subject's Ku70 alleles or regulatory regions to those alleles are deleted or different from the wild type so as to reduce or eliminate the subject's expression of polypeptide having tumor suppressor activity. This invention also provides a method of assessing the severity of cancer in a subject comprising: determining the subcellular localization of Ku70 in the subject, wherein an abnormal subcellular localization of Ku70 indicates a predisposition to cancer.

Uses of Ku70

The present invention provides a method for creating a cryoarray of frozen tissue cores using a cryoarray system. Such system comprises a tissue mold, an embedding medium and a cryoarray device. The cryoarray device comprises a mold plate, an ejector plate, mold alignment pins, ejector pins, and cryoarray pins. Such method/system may be used for preparing frozen sections with multiple tissue specimens for assays such as in-situ hybridization and immunohistochemistry.

Cryoarray system and uses thereof

Ku70&mdash;related methods

Method for detecting pre-cancerous or cancerous cells using P90

The subject invention describes a method of determining the secretor status of an individual which comprises obtaining a sample of a biological fluid from the individual and determining whether the sample includes the Lewis.sup.a or Lewis.sup.b antigens, the presence of the Lewis.sup.a antigen in the sample indicating that the individual is a nonsecretor, the presence of the Lewis.sup.b antigen in the sample indicating that the individual is a secretor, and the presence of neither antigen indicating the secretor status of the individual is inconclusive. The invention also provides a method of further determining the secretor status of an individual of having an inconclusive secretor status which comprises determining whether the biological fluid sample from the individual includes A, B or precursor type 1 chain antigens, the presence of any such antigens in the sample indicating that the individual is a secretor, the lack of any such antigens in the sample indicating that the individual is a nonsecretor. The invention provides a method of determining whether a human female subject is susceptible to urogenital infection which comprises determining whether the subject is a secretor according to the hereinabove-described methods, a secretor being susceptible to such an infection. The present application also provides a method of disstinguishing urothelial carcinoma from normal tissue, and identifying human germ cell tumor as seminoma or nonseminoma. Finally, the invention provides a panel comprising some or all of the monoclonal antibodies H 29-36 (ATCC No. HB 8248), S8 (ATCC No. HB 9036), T 174 (ATCC No. HB 8242), T 218 (ATCC No. HB 8249), P 12 (ATCC No. HB 8551), F 3 (ATCC No. HB 8217), and K 21 (ATCC No. HB 8549).

Blood group antigen panel

Antigenic profiles of renal carcinoma specimans developed with panels of monoclonal antibodies derived from several different tissues serve as useful clinical indicators for cancer type, cancer subset as well as histiogenesis and prognosis indicators.

Method for characterizing types of renal carcinoma and prognosis

A panel of monoclonal antibodies produced from normal human lung fibroblasts and human lung tumors as immunogen is used to diagnose the presence of lung tumors and differentiate between those which are benign and those which are cancerous.

Monoclonal antibodies to human lung cancers and method

Monoclonal antibodies to specific cell surface antigens of human choriocarcinoma, teratocarcinoma, and normal trophoblasts are disclosed. Additionally, panels of monoclonal antibodies which may be used in phenotyping cell and tissue samples are disclosed as well.

Choriocarcinoma monoclonal antibodies and antibody panels

Mouse monoclonal antibodies to several cell antigens of human ovarian, cervical and endometrial carcinomas have been produced and characterized. The distribution of the antigens was determined by mixed hemagglutination assays on 153 normal and malignant cell cultures of various types, and by immunoperoxidase staining of frozen sections of 27 normal adult and 24 fetal tissues. five monoclonal antibodies representative of five classes of mAb raised to restricted ovarian, cervical and endometrial cells were tested extensively producing mAb reactive with cancer but not normal cells. One such mAb, MF116 was readily detected in the spent culture medium of metabolically radiolabeled cells. These antibodies, reacting with relatively restricted cell surface antigens, are useful in the analysis of epithelial cell differentiation, in cancer diagnosis and therapy and in tissue typing of normal or abnormal cells.

Monoclonal antibodies to ovarian, cervical and uterine human cancers and

A panel of monoclonal antibodies, produced from human bladder tumors as immunogen, is used to diagnose the presence of transitional cell carcinoma in patients. The panel is also used to identify and differentiate low grade non-invasive papillomas from invasive life-threatening transitional cell carcinomas, thereby enabling decisions as to the extent of bladder surgery. These mAbs can also be used as a panel for tissue typing of normal and abnormal cell specimens.

Monoclonal antibodies to human bladder and ureter cancers and method

A panel of monoclonal antibodies produced from human gastrointestinal tumors as immunogen is used to diagnose the presence of colon cancer. The antibody panel subsets the human gastrointestinal tract in its reactivity vis-a-vis esophagus, stomach, small intestine and colon. The panel is useful as a diagnostic probe for cancer.

Monoclonal antibodies to human gastrointestinal cancers and hybridoma

Growing community of inventors

New York, NY, United States of America

Carlos Cordon-Cardo